MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiesenberg, I.
Right arrow Articles by Carlberg, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiesenberg, I.
Right arrow Articles by Carlberg, C.

Vol. 53, Issue 6, 1131-1138, June 1998

Specific Activation of the Nuclear Receptors PPARgamma and RORA by the Antidiabetic Thiazolidinedione BRL 49653 and the Antiarthritic Thiazolidinedione Derivative CGP 52608

Irmgard Wiesenberg, Michele Chiesi, Martin Missbach, Carsten Spanka, Werner Pignat, and Carsten Carlberg

Pharma Research (I.W., M.C., M.M., C.S., W.P.), Novartis Pharma AG, CH-4002 Basel, Switzerland, and Institute of Physiological Chemistry I (C.C.), Heinrich-Heine University, D-40001 Duesseldorf, Germany

The thiazolidinedione BRL 49653 and the thiazolidinedione derivative CGP 52608 are lead compounds of two pharmacologically different classes of compounds. BRL 49653 is a high affinity ligand of peroxisome proliferator-activated receptor gamma  (PPARgamma ) and a prototype of novel antidiabetic agents, whereas CGP 52608 activates retinoic acid receptor-related orphan receptor alpha  (RORA) and exhibits potent antiarthritic activity. Both receptors belong to the superfamily of nuclear receptors and are structurally related transcription factors. We tested BRL 49653 and CGP 52608 for receptor specificity on PPARgamma , RORA, and retinoic acid receptor alpha , a closely related receptor to RORA, and compared their pharmacological properties in in vitro and in vivo models in which these compounds have shown typical effects. BRL 49653 specifically induced PPARgamma -mediated gene activation, whereas CGP 52608 specifically activated RORA in transiently transfected cells. Both compounds were active in nanomolar concentrations. Leptin production in differentiated adipocytes was inhibited by nanomolar concentrations of BRL 49653 but not by CGP 52608. BRL 49653 antagonized weight loss, elevated blood glucose levels, and elevated plasma triglyceride levels in an in vivo model of glucocorticoid-induced insulin resistance in rats, whereas CGP 52608 exhibited steroid-like effects on triglyceride levels and body weight in this model. In contrast, potent antiarthritic activity in rat adjuvant arthritis was shown for CGP 52608, whereas BRL 49653 was nearly inactive. Our results support the concept that transcriptional control mechanisms via the nuclear receptors PPARgamma and RORA are responsible at least in part for the different pharmacological properties of BRL 49653 and CGP 52608. Both compounds are prototypes of interesting novel therapeutic agents for the treatment of non-insulin-dependent diabetes mellitus and rheumatoid arthritis.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. Acuna-Castroviejo
A new guest playing with bone and fat
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2007; 292(6): R2206 - R2207.
[Full Text] [PDF]

Home page
 CVIHome page
G. Wildner and M. Diedrichs-Moehring
Multiple Autoantigen Mimotopes of Infectious Agents Induce Autoimmune Arthritis and Uveitis in Lewis Rats
Clin. Vaccine Immunol., May 1, 2005; 12(5): 677 - 679.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Arici, R. Chana, A. Lewington, J. Brown, and N. J. Brunskill
Stimulation of Proximal Tubular Cell Apoptosis by Albumin-Bound Fatty Acids Mediated by Peroxisome Proliferator Activated Receptor-{gamma}
J. Am. Soc. Nephrol., January 1, 2003; 14(1): 17 - 27.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
V. van Harmelen, A. Dicker, M. Ryden, H. Hauner, F. Lonnqvist, E. Naslund, and P. Arner
Increased Lipolysis and Decreased Leptin Production by Human Omental as Compared With Subcutaneous Preadipocytes
Diabetes, July 1, 2002; 51(7): 2029 - 2036.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
T. Murata, Y. Hata, T. Ishibashi, S. Kim, W. A. Hsueh, R. E. Law, and D. R. Hinton
Response of Experimental Retinal Neovascularization to Thiazolidinediones
Arch Ophthalmol, May 1, 2001; 119(5): 709 - 717.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. Murata, S. He, M. Hangai, T. Ishibashi, X.-P. Xi, S. Kim, W. A. Hsueh, S. J. Ryan, R. E. Law, and D. R. Hinton
Peroxisome Proliferator-Activated Receptor-{gamma} Ligands Inhibit Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., July 1, 2000; 41(8): 2309 - 2317.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
K. Bordji, J.-P. Grillasca, J.-N. Gouze, J. Magdalou, H. Schohn, J.-M. Keller, A. Bianchi, M. Dauca, P. Netter, and B. Terlain
Evidence for the Presence of Peroxisome Proliferator-activated Receptor (PPAR) alpha and gamma and Retinoid Z Receptor in Cartilage. PPARgamma ACTIVATION MODULATES THE EFFECTS OF INTERLEUKIN-1beta ON RAT CHONDROCYTES
J. Biol. Chem., April 14, 2000; 275(16): 12243 - 12250.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. Giguère
Orphan Nuclear Receptors: From Gene to Function
Endocr. Rev., October 1, 1999; 20(5): 689 - 725.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics